Nustendi 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0026 
C.I.z - Changes (Safety/Efficacy) of Human and 
19/04/2022 
PL 
To update the local representatives in CZ and SL. In addition 
Veterinary Medicinal Products - Other variation 
the MAH has taken to opportunity to correct an error in the 
ES SmPC. 
IB/0025 
B.II.b.3.z - Change in the manufacturing process of 
11/03/2022 
n/a 
the finished or intermediate product - Other variation 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are 
issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD 
is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
PSUSA/10841
Periodic Safety Update EU Single assessment - 
10/03/2022 
n/a 
PRAC Recommendation - maintenance 
/202108 
bempedoic acid, bempedoic acid / ezetimibe 
WS/2177/G 
This was an application for a group of variations 
13/01/2022 
n/a 
following a worksharing procedure according to Article 
20 of Commission Regulation (EC) No 1234/2008. 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where batch 
control/testing takes place 
B.I.a.1.g - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Introduction of a new manufacturer of the AS that is 
not supported by an ASMF and requires significant 
update to the relevant AS section in the dossier 
IB/0024/G 
This was an application for a group of variations. 
10/01/2022 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.e.5.a - Implementation of changes foreseen in an 
approved change management protocol - Requires no 
further supportive data 
B.I.e.5.a - Implementation of changes foreseen in an 
approved change management protocol - Requires no 
further supportive data 
B.I.e.5.a - Implementation of changes foreseen in an 
approved change management protocol - Requires no 
Page 2/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
further supportive data 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process of 
the AS 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
IB/0023 
C.I.11.z - Introduction of, or change(s) to, the 
04/01/2022 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0018 
C.I.z - Changes (Safety/Efficacy) of Human and 
17/10/2021 
SmPC 
Veterinary Medicinal Products - Other variation 
PSUSA/10841
Periodic Safety Update EU Single assessment - 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
/202102 
bempedoic acid, bempedoic acid / ezetimibe 
IB/0019/G 
This was an application for a group of variations. 
25/08/2021 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process of 
the AS 
Page 3/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where batch 
control/testing takes place 
B.I.a.4.c - Change to in-process tests or limits applied 
during the manufacture of the AS - Deletion of a 
non-significant in-process test 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.b.2.a - Change in test procedure for AS or starting 
material/reagent/intermediate - Minor changes to an 
approved test procedure 
B.I.b.2.a - Change in test procedure for AS or starting 
material/reagent/intermediate - Minor changes to an 
approved test procedure 
IB/0017 
B.II.d.1.z - Change in the specification parameters 
17/08/2021 
n/a 
and/or limits of the finished product - Other variation 
WS/2083/G 
This was an application for a group of variations 
08/07/2021 
n/a 
following a worksharing procedure according to Article 
20 of Commission Regulation (EC) No 1234/2008. 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
Page 4/9 
 
 
 
 
 
 
 
 
 
 
 
 
of studies to the competent authority 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IAIN/0016/G 
This was an application for a group of variations. 
02/06/2021 
17/06/2021 
Annex II and PL 
B.I.e.5.a - Implementation of changes foreseen in an 
approved change management protocol - Requires no 
further supportive data 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.7 - Administrative change - Deletion of 
manufacturing sites 
II/0007 
C.I.13 - Other variations not specifically covered 
15/04/2021 
n/a 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
PSUSA/10841
Periodic Safety Update EU Single assessment - 
11/03/2021 
n/a 
PRAC Recommendation - maintenance 
/202008 
bempedoic acid, bempedoic acid / ezetimibe 
IB/0013 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf life 
19/02/2021 
17/06/2021 
SmPC 
Page 5/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of the finished product - As packaged for sale 
(supported by real time data) 
IB/0012 
B.II.b.3.z - Change in the manufacturing process of 
10/02/2021 
n/a 
the finished or intermediate product - Other variation 
IB/0011/G 
This was an application for a group of variations. 
06/01/2021 
n/a 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold increase 
compared to the originally approved batch size 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
IB/0010/G 
This was an application for a group of variations. 
10/12/2020 
17/06/2021 
SmPC, Annex 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
A.6 - Administrative change - Change in ATC 
Code/ATC Vet Code 
II, Labelling 
and PL 
IA/0008/G 
This was an application for a group of variations. 
06/11/2020 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process of 
the AS 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where batch 
Page 6/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
control/testing takes place 
IB/0006/G 
This was an application for a group of variations. 
27/10/2020 
n/a 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.2.e - Change in test procedure for AS or starting 
material/reagent/intermediate - Other changes to a 
test procedure (including replacement or addition) for 
the AS or a starting material/intermediate 
IB/0005/G 
This was an application for a group of variations. 
31/07/2020 
n/a 
B.I.b.1.h - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition or 
replacement (excl. Biol. or immunol. substance) of a 
specification parameter as a result of a safety or 
quality issue 
B.I.b.1.h - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition or 
replacement (excl. Biol. or immunol. substance) of a 
specification parameter as a result of a safety or 
quality issue 
IAIN/0004/G 
This was an application for a group of variations. 
17/07/2020 
17/06/2021 
SmPC, 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
Labelling and 
PL 
Page 7/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. tablets, 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
II/0002 
C.I.13 - Other variations not specifically covered 
09/07/2020 
n/a 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IB/0003/G 
This was an application for a group of variations. 
05/06/2020 
n/a 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
T/0001 
Transfer of Marketing Authorisation 
07/05/2020 
02/06/2020 
SmPC, 
Page 8/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Labelling and 
PL 
Page 9/9 
 
 
 
 
 
 
 
